Blue Cross and Blue Shield of Vermont and The Vermont Health Plan
Osteoporosis Agents
Risedronate; Fosamax D®, Binosto®, and Atelvia®
Step Therapy Guidelines

DESCRIPTION: Bisphosphonates inhibit bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption direction, leading to an indirect decrease in bone formation.

INDICATION(S): Treatment and prevention of Osteoporosis in postmenopausal females
Treatment of osteoporosis in males
Treatment of Paget’s disease in symptomatic patients at risk of complications
Treatment of glucocorticoid induced osteoporosis

REASONS FOR Step Therapy: ☒ Cost ☐ Potential for misuse ☐ Toxicity

CRITERIA for APPROVAL: The patient has had a 30-day trial and failure of alendronate or ibandronate prior to trying risedronate, Fosamax-D, Atelvia, or Binosto

REASONS for DENIAL of BENEFIT: Patient does not meet above criteria.

BENEFIT APPROVAL: Approval for two years.